Figure 2.
Overall survival through Week 24 from the start of sunitinib treatment. (A) Safety analysis population (N = 1671). (B) By RDI during the first 6 weeks of treatment among 1618 patients with dose/duration data for this period. (C) By metastatic site at baseline. (D) By prior systemic drug treatment.